Greenleaf Trust Sells 1,030 Shares of Edwards Lifesciences Co. (NYSE:EW)

Greenleaf Trust decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,401 shares of the medical research company’s stock after selling 1,030 shares during the period. Greenleaf Trust’s holdings in Edwards Lifesciences were worth $2,699,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Castleview Partners LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $25,000. Compass Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $31,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $34,000. Janiczek Wealth Management LLC increased its stake in shares of Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after purchasing an additional 303 shares in the last quarter. Finally, Operose Advisors LLC increased its stake in shares of Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,715 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the sale, the vice president now directly owns 17,213 shares in the company, valued at approximately $1,566,038.74. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the completion of the sale, the vice president now directly owns 17,213 shares in the company, valued at approximately $1,566,038.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the sale, the director now owns 4,486 shares of the company’s stock, valued at $388,801.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

EW stock opened at $85.94 on Friday. The stock has a market cap of $51.73 billion, a PE ratio of 37.37, a P/E/G ratio of 4.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The firm has a 50 day simple moving average of $90.15 and a two-hundred day simple moving average of $78.31.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.64 EPS. On average, analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Evercore ISI lifted their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Oppenheimer boosted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Finally, OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.